posted on 2025-08-02, 12:30authored byF Vecchio, A Carré, D Korenkov, Z Zhou, P Apaolaza, S Tuomela, O Burgos-Morales, I Snowhite, J Perez-Hernandez, B Brandao, G Afonso, C Halliez, J Kaddis, SC Kent, M Nakayama, SJ Richardson, J Vinh, Y Verdier, J Laiho, R Scharfmann, M Solimena, Z Marinicova, E Bismuth, N Lucidarme, J Sanchez, C Bustamante, P Gomez, S Buus, nPOD-Virus Working Group, S You, A Pugliese, H Hyoty, T Rodriguez-Calvo, M Flodstrom-Tullberg, R Mallone
Coxsackievirus B (CVB) infection of pancreatic β cells is associated with β cell autoimmunity and type 1 diabetes. We investigated how CVB affects human β cells and anti-CVB T cell responses. β cells were efficiently infected by CVB in vitro, down-regulated human leukocyte antigen (HLA) class I, and presented few, selected HLA-bound viral peptides. Circulating CD8+ T cells from CVB-seropositive individuals recognized a fraction of these peptides; only another subfraction was targeted by effector/memory T cells that expressed exhaustion marker PD-1. T cells recognizing a CVB epitope cross-reacted with β cell antigen GAD. Infected β cells, which formed filopodia to propagate infection, were more efficiently killed by CVB than by CVB-reactive T cells. Our in vitro and ex vivo data highlight limited CD8+ T cell responses to CVB, supporting the rationale for CVB vaccination trials for type 1 diabetes prevention. CD8+ T cells recognizing structural and nonstructural CVB epitopes provide biomarkers to differentially follow response to infection and vaccination.
Funding
115797 (INNODIA)
22/0006504
3-PDF-2020-942-A-N
3-SRA-2017-492-A-N
945268 (INNODIA HARVEST)
ANR-19-CE15-0014-01
Agence Nationale de la Recherche
EQU20193007831
Federal Ministry for Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.)
Fondation pour la Recherche Medicale
HANDEL-I; RRID:SCR_021947
Human Atlas of Neonatal Development and Early Life Immunity program
This is the final version. Available on open acess from the American Association for the Advancement of Science via the DOI in this record.
Data and materials availability: Immunopeptidomics datasets have
been deposited under PRIDE: PXD042711. All other data needed to evaluate the conclusions in
the paper are present in the paper and/or the Supplementary Materials. All unique/stable
reagents generated in this study can be provided by R.M. pending scientific review and a
completed materials transfer agreement. Requests should be submitted to roberto.mallone@
inserm.fr.